AlphAIalphai — Financial news for AI agents
Zacks CommentaryOCT 132 min read$DH

What Makes Definitive Healthcare (DH) a New Buy Stock

Definitive Healthcare (DH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 13, 2025, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 14, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
What Makes Definitive Healthcare (DH) a New Buy Stock — source image
Source · www.zacks.com
Decision brief

The 30-second read

$DHBullishHigh
01

Why it matters

The upgrade signals increased investor confidence, likely leading to short-term buying interest.

02

Market read

The news is highly relevant for traders focusing on healthcare technology stocks, especially DH.

03

What to watch

Potential overreliance on analyst upgrades; broader market volatility or sector-specific risks could offset gains.

Timing: short-term (next 1-2 weeks)

Background

Definitive Healthcare has recently been upgraded to Zacks Rank #2 (Buy), reflecting improved earnings prospects amid positive analyst sentiment.

Company-level read

Ticker impact

$DHBullishHigh confidence
Context

The news indicates a positive upgrade and increased optimism about Definitive Healthcare's earnings prospects, which could influence trading decisions.

Expected impact

Moderate upward movement in the near term, approximately 3-5% increase over the next 1-2 weeks.

Evidence & confidence

The upgrade reflects a consensus shift among analysts and is supported by improved earnings outlooks, making it a reliable indicator for short-term traders.

Market effects

Sector

The healthcare technology sector may experience positive sentiment, potentially lifting related stocks.

Regional

Limited regional impact; primarily affects US-based healthcare tech stocks.

Global

Minimal; the news is specific to a US-listed healthcare company.

Counterpoint

What could challenge this read

The upgrade may already be priced in, and the stock could experience a short-term correction or consolidation.

Key entities

  • Company
    Definitive Healthcare

    A healthcare technology company providing data and analytics.

  • Research Firm
    Zacks Investment Research

    The source of the stock rating upgrade.

Read at source← All news

Related articles

AUG 18
$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

fool.com6 min
AUG 10
$DHHigh

Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea

SEC EDGAR 8-K6 min
AUG 24
$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

yahoo.com2 min
AUG 23
$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

ozarab.media2 min
AUG 23
$PBRMed

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Pemex and Petrobras are collaborating to explore deep, high-risk oil prospects in the Gulf of Mexico. Pemex, facing declining production and high debt, seeks to unlock potential resources in Jurassic formations. Petrobras, with extensive pre-salt drilling experience, brings technical expertise. Success could reverse Pemex's fortunes, but risks remain high. Pemex reported a 70% net profit drop in Q2 2024, producing 1.66 million bpd, below government targets.

oilprice.com3 min